Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi's agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology- lapscovery. The second position goes to the…

ByPrince GiriFebruary 11, 2021

TOP 20

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed- the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or…

ByPrince GiriOctober 22, 2020

TOP 20

Top 20 Oncology Companies by Total Products of 2019

To remain successful in the oncology market- change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However- despite robust levels of pipeline activity- oncology remains a challenging area for research…

ByPrince GiriSeptember 24, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – June 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019. PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorJune 30, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2020

The US FDA has approved multiple NDAs and BLAs in May 2020, leading to the treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 43 novel products so far in 2020, including 12 in May 2020…

BySenior EditorJune 19, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorMay 29, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2019 and January 2020

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019 However, there is a significant increase in multiple diseases while the new approvals are helping and advancing the changes to understand, diagnose and treat the diseases Our team…

BySenior EditorFebruary 21, 2020

INSIGHTS+

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales promotion…

BySenior EditorJanuary 10, 2020

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…

BySenior EditorSeptember 7, 2019

INSIGHTS+

Insights+: Key Events of ASCO 2019

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of ASCO 2019, 2400+ abstracts were presented. IBM Watson Health was also a part of ASCO 2019 with its advancement in Oncology, Genomics and Patient Monitoring.…

BySenior EditorJuly 6, 2019

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Top 20 Oncology Companies by Total Products of 2019

Insights+: COVID-19 Healthcare News Monthly Updates – June 2020

Insights+: The US FDA New Drug Approvals in May 2020

Insights+: COVID-19 Healthcare News Monthly Updates – May 2020

Insights+: The US FDA New Drug Approvals in December 2019 and January 2020

PharmaShots’ Most Read News of 2019

PharmaShots’ Key Highlights of Third Quarter 2019

Insights+: Key Events of ASCO 2019

Contact US

FOLLOW US